Information Provided By: 
Fly News Breaks for January 2, 2019
THOR
Jan 2, 2019 | 07:08 EDT
H.C. Wainwright analyst Debjit Chattopadhyay started Synthorx with a Buy rating and $30 price target. The company's Expanded Genetic Alphabet technology gives it the ability to manipulate the innate biological interaction of cytokines and adapt them to applications either in oncology or autoimmune diseases, "expanding the versatility and scope of the platform," says the analyst.
News For THOR From the Last 2 Days
There are no results for your query THOR
